Borage oil 1g capsules
Borage oil, or borage seed oil, is a rich source of gamma-linolenic acid (GLA) that is obtained from the seeds of the Borago officinalis (borage).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 6 · Randomised trials: 5 · 1997–2026
Showing the 50 most relevant studies, sorted by most relevant.
Santos Filipe M, Bangay G, Brauning FZ, et al.
2025
Background:Coleus amboinicus (Lour.) (syn Plectranthus amboinicus) from the Lamiaceae family-a large family of aromatic herbs with many medicinally important species-is a frequently cited species within the Plectranthus genus, renowned for its traditional uses, phytochemical composition, biological activities, and applications in skin care. Methods: A systematic review was conducted following PRISMA guidelines to provide an in-depth understanding of P. amboinicus' phytochemical composition and biological activity, particularly in dermatological contexts, underscoring its significance in traditional medicine and modern phytochemical research. Results: P. amboinicus extracts and essential oils exhibit significant antimicrobial activity against both Gram-positive and Gram-negative bacteria, and notable antifungal properties, particularly against dermatophytes. Additionally, the species demonstrates remarkable mosquito repellent and anti-parasitic effects, comparable to DEET, and potent anti-inflammatory properties by inhibiting pro-inflammatory cytokines. The plant's rich polyphenolic content contributes to its significant antioxidant properties, preventing conditions like hyperpigmentation and premature aging. P. amboinicus also exhibits cytotoxic activity against various cancer cell lines and promotes wound healing through its analgesic, anti-inflammatory, and antioxidant abilities. Conclusions: This comprehensive exploration of P. amboinicus validates its diverse therapeutic potential across infectious diseases, oncology, and wound care. Further research and clinical trials are warranted to fully elucidate its mechanisms of action and optimize its therapeutic applications, paving the way for its integration into mainstream medical practices.
Abstract licence: CC BY
Mary S Fewtrell, Rebecca A Abbott, Kathy Kennedy, et al.
The Journal of Pediatrics, 2004
- Infant, Premature
- Milk, Human
- Weight Gain
Joel TM Bamford, Sujoy Ray, Alfred Musekiwa, et al.
Cochrane Database of Systematic Reviews, 2013
- Oenothera biennis
- Dermatitis, Atopic
- Eczema
Intakhiao S, Suwannarat W, Subongkot T, et al.
2026
Jin A. Shin, Meixiang Sun, Jong‐Moon Jeong
Lipids, 2020
- Melanocytes
- Camellia
- Melanoma, Experimental
Takwale A, Tan E, Agarwal S, et al.
2003
- Dermatitis, Atopic
- gamma-Linolenic Acid
- Plant Oils
Chrzanowska E, Denisow B, Ekiert H, et al.
2024
- Boraginaceae
- Plant Extracts
- Cosmetics
One of the challenges of the pharmaceutical and cosmetic industries is to deliver biochemical compounds that can be advantageous for the skin. Research on Boraginaceae taxa has confirmed their use in traditional medicine and proved the potential biological importance of various molecules in cosmetology. The main classes of valuable compounds associated with Boraginaceae taxa are fatty acids, including γ-linolenic acid, essential oils, phenolic acids (e.g., rosmarinic acid), flavonoids, anthocyanins, tannins, and saponins. Highly specific are naphthoquinone pigments (including shikonin) and allantoin. Another distinguishing feature is the accumulation of silica (silicon dioxide) in trichomes. Some taxa produce mucilages. However, pyrrolizidine alkaloids (PAs) with toxic properties are also found (mainly in Symphytum spp.); therefore, their applications should be avoided. Extracts or individual compounds of Boraginaceae plants are characterized by antioxidant, anti-inflammatory, antiseptic, anti-irritant, antiaging, and photoprotective activities. Boraginaceae products are widespread in the cosmetic industry as ingredients of creams, balms, lotions, gels, shampoos, lipsticks, perfumes, and deodorants. The most valuable for the cosmetic industry are raw materials obtained from the genera Alcanna Anchusa, Arnebia, Borago, Buglossoides, Cerinthe, Cordia, Echium, Ehretia, Eriodictyon, Glendora, Lappula, Lithospermum, Lycopsis, Macrotomia, Maharanga, Mertensia, Messerschmidia, Myosotis, Omphalodes, Onosma, Pulmonaria, Rindera, Symphytum, Trachystemon, and Trigonotis. Further research should focus on the search for active substances in other plants of the family.
Abstract licence: CC BY
Bellisai G, Bernasconi G, Cabrera LC, et al.
2024
The applicant Detia Freyberg GmbH submitted to the competent national authority in Germany two requests to evaluate the confirmatory data that were identified for tree nuts, oilseeds, cereals and commodities of animal origin in the framework of the maximum residue level (MRL) review under Article 12 of Regulation (EC) No 396/2005 as not available and two requests in accordance with Article 6 of Regulation (EC) No 396/2005 to increase the existing MRL for the active substance aluminium phosphide in peanuts, barley, oat, rye, rice and wheat, roots of herbal infusions, cocoa beans and seed spices and for the active substance magnesium phosphide in oilseeds (except peanuts) and pistachios. The four applications were combined by EFSA under the current assessment. To address the data gaps, validation data for the method of analysis for enforcement of phosphide in high-oil content commodities and new residue trials were submitted. The data gaps on additional residue trials supporting authorisations on oilseeds and cereal grains, on clarifications regarding the discrepancies observed in the residue trial results for pistachios, and on data confirming the negligible occurrence of phosphane and its oxidation products in livestock products were considered addressed. The data gap on independent laboratory validation (ILV) and a confirmatory method for monitoring of phosphide in high-oil content commodities was considered not fully addressed. The information provided justified a lowering of the current tentative MRLs for the whole group of cereals (except rice and 'others'), an increase of the current tentative MRLs for pistachios, the whole group of oilseeds, rice and 'other' cereals, herbal infusions from roots, cocoa beans and seed spices, and a revision of the risk assessment performed for phosphane and its phosphide salts. Based on the risk assessment results, EFSA concluded that the short-term and long-term intake of residues resulting from the use of AlP and Mg3P2 according to the reported agricultural practices is unlikely to present a risk to consumer health. Further risk management considerations are required.
Abstract licence: CC BY-ND
Ruaa Mohammed Ibrahim, Dhuha Abdul Saheb Alshammaa
Iraqi Journal of Pharmaceutical Sciences, 2023
Kostrakiewicz-Gierałt K
2025
- Plant Oils
- Sports
- Sports Nutritional Physiological Phenomena
Background/Objectives. Edible oils derived from herbaceous and woody plants are an important nutritional resource, assuring the health and performance of sportspeople. The aim of this study was to review the inventions and experimental articles referring to the application of vegetable oils in food products for sportspeople and published in the period of 2015-2024. Methods. The literature search was conducted across Google Scholar, Scopus, and ISI Web of Science databases, as well as by using Google Patents and Espacenet Patent search engines. Results. Altogether, 58 patents and 35 original articles were found. In total, the use of 39 plant taxa belonging to 27 botanical families was documented. The majority of disclosures refer to sports nutrition, post-exercise recovery support, and/or sport performance improvement and may be provided in the form of powders, tablets, beverages, and/or capsules. According to the reviewed studies, the consumption of olive, walnut, and perilla oils beneficially affects the morphological, physiological, and biochemical indicators of sportspeople. The substantial intake of olive oil reported by sportspeople from southern Europe is linked to the recommendations of the Mediterranean diet, while lower consumption of other vegetable oils might be connected to focusing on intake of carbohydrates and/or proteins and/or consumption of other fat sources such as seeds or nuts. Conclusions. Considering the great potential of useful plant species, it might be concluded that future investigations should focus on both (i) further investigations of the effects of well-known vegetable oils on the health and performance of sportspeople, and (ii) searching for novel plant oil sources, suitable for the preparation of food products dedicated to amateur and professional sportspeople.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 90 interactions
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Borage oil
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72